跳至主要内容
临床试验/NCT03751735
NCT03751735已完成1 期

Evaluation of the Efficacy for Two Doses of Intracavernous Injection of Wharton Jelly Stem Cells for the Treatment of Diabetic Erectile Dysfunction

Sophia Al-Adwan2 个研究点 分布在 1 个国家目标入组 9 人开始时间: 2017年1月27日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
9
试验地点
2
主要终点
Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaires

研究概览

简要总结

Efficacy of Intracavernous injection of Wharton jelly Mesenchymal stem cells for the treatment of erectile dysfunction in diabetic patients.

详细描述

This study will be conducted at the Cell Therapy Center (CTC), Jordan, in which 22 male patients ranging from 25-70 years diagnosed with erectile dysfunction will be selected. This diagnosis is based on medical history, validated questionnaires, physical examinations, laboratory tests and specific diagnostic tests.

The patients are followed by clinical assessment, laboratory investigations as well as Doppler ultrasound.

The investigators hypothesize that the intracavernous injection of stem cells will facilitate the recovery of erectile function resulting in satisfying clinical outcomes in patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
25 Years 至 70 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Adult male patients ranging from 25 to 70 years.
  • History of chronic erectile dysfunction for at least six months.
  • Baseline international index of erectile function (IIEF) score of <
  • Not interested or able to use phosphodiesterase type 5 inhibitor (PD5i) drug therapy and willing to forgo theses treatments for the first 6 month period following study treatment.
  • Body Mass Index between 20-
  • Willing to provide written informed consent, complete questionnaire, and to be available for all baseline treatment and follow up examinations required by protocol.

排除标准

  • Current urinary tract or bladder infection.
  • Clinical/Laboratory evidence of transmissible diseases.
  • Clinically evident penile anatomical deformities(e.g., Peyronie's disease) or history of priapism.
  • Skin irritation, infection, wound, sore or disruption in the immediate areas of skin entry for penile injection.
  • Current or previous malignancy.
  • Use of any non study treatment for erectile function within 4 weeks of study treatment.
  • Lack of willingness to continue through 6 months after study treatment.
  • Any previous penile implant or penile vascular surgery.
  • Uncontrolled hypertension or hypotension(systolic blood pressure > 170 or < 90 mm Hg, and diastolic blood pressure > 100 or < 50 mm Hg).
  • Reported unstable cardiovascular disease (e.g., unstable angina, myocardial infarction within past 6 months, cardiac failure or life-threatening arrhythmia, congestive heart failure) or symptomatic postural hypotension within 6 months before screening.
  • Bleeding or clotting disorder, use of anticoagulant therapy.
  • Lab values for complete blood count (CBC), prothrombin time (PT)/ partial thromboplastin time (PTT)/ international normalized ratio (INR), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and creatinine falling outside the normal lab values.
  • Systemic autoimmune disorder.
  • Significant active systemic or localized infection.
  • Receiving immunosuppressant medications.
  • Post-radical prostatectomy.

研究组 & 干预措施

Dose 1

Experimental

Dose I of Wharton Jelly Mesenchymal stem cells (WJ-MSC) Two intracavernous injections of 20 million of WJ-MSC cells will be given to erectile dysfunction patients at baseline and 4th week of follow up

干预措施: Wharton Jelly Mesenchymal stem cells (Biological)

结局指标

主要结局

Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaires

时间窗: 12 months

The efficacy of the intracavernous injection of Wharton Jelly will be evaluated by scoring the SHIM/IIEF/EHS questionnaires.

Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by Penile Doppler ultrasonography.

时间窗: 12 months

Patients will be evaluated for the efficacy of the intracavernous injection of Wharton Jelly derived Mesenchymal Stem Cells by Penile Doppler ultrasonography in which peak systolic velocity of the cavernosal arteries will be measured.

次要结局

未报告次要终点

研究者

发起方
Sophia Al-Adwan
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Sophia Al-Adwan

Researcher, Clinical coordinator

University of Jordan

研究点 (2)

Loading locations...

相似试验